The clinical course of familial hypokalaemic periodic paralysis (FHPP) is characterised by transient paralytic attacks associated with decreased serum potassium and chronic progressive muscular weakness. Hypokalaemic attacks are usually prevented with oral administration of potassium, spironolactone or acetazolamide. We report a case where such treatments became progressively ineffective. The episodic character of the disease led us to test lithium gluconate as addon therapy in so far as lithium effects on cellular potassium fluxes are known. The drug was first introduced in an open trial and a reduction in the frequency of attacks were observed. A randomised, placebo-controlled, cross-over study was then carried out.
A 45 year old mechanic had experienced periodic paralytic attacks since the age of 15 years. The investigation of his pedigree revealed 15 comparable familial cases among four generations. During paralytic attacks hypokalaemia as low as 2 3 mmol/l was confirmed. Thyroid function tests were normal. Limbs and trunk muscles were involved but respiratory, facial and oesophageal musculature were not affected. Between attacks plasma potassium levels were normal. He was given oral supplementation ofpotassium (5 to 8 g daily) and there was an improvement in the severity of attacks. Acetazolamide and spironolactone were then successively introduced without serious effect. For the past two years, paralytic attacks occurred at a mean rate of once a week. Permanent muscular weakness increased progressively and socio-professional adjustment became necessary.
Lithium gluconate (5 ml ampoules: Li 4 95 mmol and NaCl 0 05 g; Neurolithium, Labcatal laboratories) was introduced. To begin with the patient was given lithium during an open trial, potassium being continued as before. The lithium daily dose was one ampoule from week 1-6, two ampoules from week 7-12, two and three ampoules each other day from week 13-23, and one ampoule from week [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] On the hypothesis that the marked hyper-*phagia might be due to reduction in effective 5-HT function he was treated with fluvoxamine (a selective 5-HT uptake blocker) 100 mg/day for four weeks. The She was reluctant to complain at first as she felt her old neighbours "had so few pleasures left to them". After a few days the continuous and repetitive tunes became so irksome that she asked her home-help to make discrete enquiries. She was dismayed to learn that her neighbours had not bought a new music centre. Sometime later her son visited and she described to him the sounds she was hearing.
He realised that there was no basis for his mother's complaints and initiated a series of medical referrals through the family doctor. The ENT surgeons prescribed a tinnitus
